Loading
A phase 1/2 trial of BIO-106, Pembrolizumab in metastatic cancer, run by BiOneCure Therapeutics Inc., now recruiting.
A Study in Patients With Advanced Cancers is a phase 1/2 interventional study registered as NCT05320588 by BiOneCure Therapeutics Inc., with 332 participants planned, started 2022-03-25 and due to reach its primary completion in 2024-04. Interventions recorded: BIO-106, Pembrolizumab. Conditions listed: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/